Short interest for Myriad Genetics gives investors a sense of the degree to which investors are betting on the decline of Myriad Genetics's stock. Short interest data is updated every two weeks.

Myriad Genetics Stock (NASDAQ:MYGN), Short Interest Report

Myriad Genetics

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Analyst Color

News

Health Care

Initiation

Small Cap

Analyst Ratings

General

MYGN

Piper Sandler initiated coverage on Myriad Genetics Inc (NASDAQ: MYGN), noting that many investors know the company as one of the earliest pioneers of genetic testing.

Genetic Testing Pioneer Myriad Genetics&#39; Evolution Draws Analyst Attention Amid New Product(s) Anticipation

Penny Stocks

Intraday Update

Markets

Movers

Trading Ideas

AFIB

AFRM

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

ASLE

ASRT

ASTR

ATRA

BILL

Bakkt Holdings, Inc. Class A Common Stock

BKKT

CART

CCCS

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CDLX

CFRX

CIFR

CLMT

COOK

DNUT

FOSL

FREY

GDRX

HNST

HTCR

IKNA

Intelligent Bio Solutions Inc. - Common Stock

INBS

INFN

INSE

JRVR

LAZR

MARA

MODG

NVTA

PAHC

PUBM

RAMP

RIOT

RMCO

RVNC

SLGC

SNES

SPCE

TAST

Tempest Therapeutics, Inc. - Common Stock

TPST

WLDS

Gainers


	Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 83.5% to $0.4169 after reporting first-quarter results.


Why AMC Entertainment Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Pre-Market Outlook

APPS

FVRR

U.S. stock futures traded mostly higher this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session.

AerSale, Topgolf Callaway Brands, Digital Turbine And Other Big Stocks Moving Lower In Thursday&#39;s Pre-Market Session

Myriad Genetics Inc

Biotech

New Myriad Genetics Published Study Demonstrating PPV For 22122.2 Microdeletion Screening Using Prequel Prenatal Screen

Myriad Genetics Research Shows Reduction In Hospitalizations For Patients With Depression After GeneSight Testing

Reported Earlier, Myriad Genetics Granted Foundational Patent For Molecular Residual Disease (MRD) With Early Priority Date

<p>U.S. Patent No. 11,932,907, titled&nbsp;<em>Fetal Sex Determination Using Capillary Blood From Upper Arm</em><em>,&nbsp;</em>provides protection for Myriad&#39;s SneakPeek Snap&reg; products in the U.S through 2040.</p>


Myriad Genetics Says US Patent And Trademark Office Has Granted Patent That Covers Use Of Push-Button Blood Collection Devices For PCR-Based Fetal Sex Determination

Guidance

Myriad Genetics Sees 2024 Adj. EPS $0.00-$0.05 vs $(0.01) Est., Revenue $820M-$840M vs $819.25M Est.

<p><strong>Myriad Genetics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) reported its Q4 earnings results on Tuesday, February 27, 2024 at 04:05 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Myriad Genetics beat estimated earnings by 300.0%, reporting an EPS of $0.04 versus an estimate of $0.01.</p>
<p>Revenue was up $18.80 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat on EPS by $0.05 which was followed by a 9.0% increase in the share price the next day.</p>
<p>Here's a look at Myriad Genetics's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2023</strong></th>
<th><strong>Q2 2023</strong></th>
<th><strong>Q1 2023</strong></th>
<th><strong>Q4 2022</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.08</td>
<td>-0.08</td>
<td>-0.19</td>
<td>-0.16</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.03</td>
<td>-0.08</td>
<td>-0.21</td>
<td>-0.12</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>179.25M</td>
<td>187.13M</td>
<td>171.55M</td>
<td>169.46M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>191.90M</td>
<td>183.50M</td>
<td>181.20M</td>
<td>177.80M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Myriad Genetics <a href="https://www.benzinga.com/quote/MYGN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings

Myriad Genetics: Q4 Earnings Insights

<p>Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.01 by 300 percent.  The company reported quarterly sales of $196.60 million which beat the analyst consensus estimate of $194.78 million by 0.93 percent.  This is a 10.57 percent increase over sales of $177.80 million the same period last year.</p>


Earnings Beats

Myriad Genetics Q4 2023 Adj EPS $0.04 Beats $0.01 Estimate, Sales $196.60M Beat $194.78M Estimate

<p><a href="https://www.globenewswire.com/Tracker?data=7W34NLYNZNjFTO69eE54wvIrMCkFPlW8mqyTdOz8WoWOLbz6m0BKr7zFap2LCItgZEzbzc0YDKYYrku2Y_gqEh6KzMrHnBGDO6O23ayaQ0g=">Myriad Genetics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), a leader in genetic testing and precision medicine, today announced a research collaboration with the National Cancer Center Hospital East (NCCHE) in Japan to study the prognostic and predictive value of molecular residual disease (MRD) testing. The SCRUM-MONSTAR-SCREEN-3 study will use Myriad's ultra-sensitive MRD test, Precise MRD, to monitor circulating tumor DNA (ctDNA) over time in patients diagnosed with a wide array of solid tumor and hematological cancers.<br /><br />&nbsp;</p>
<p>The SCRUM-MONSTAR-SCREEN-3 study, led by Dr. Takayuki Yoshino of the NCCHE, will explore how multi-omic profiling can be used to develop more personalized treatment and therapeutic strategies in three study cohorts. Two of the three cohorts, including approximately 1,200 patients across more than 20 cancer types, will undergo MRD monitoring via Precise MRD. The goal of SCRUM-MONSTAR-SCREEN-3 is to generate high-quality, prospective, clinical evidence showing MRD testing can be broadly applied across cancer types and to patients with different disease severity or staging.</p>
<p>"First generation MRD tests have made remarkable progress monitoring disease recurrence and progression in cancer types with high tumor or variant burden. However, the SCRUM-MONSTAR-SCREEN-3 study requires an MRD test that is sensitive enough to use for cancers with low tumor shedding or variant burden," said Dr. Yoshino, Deputy Director of Hospital East, Head, Division for the Promotion of Drug and Diagnostic Development, Chief, Department of Gastrointestinal Oncology at NCCHE. "We are pleased to partner with Myriad, as its MRD assay is uniquely capable of detecting ctDNA at the lowest levels of detection, a necessary attribute for a pan-cancer study. This study has the potential to revolutionize the scope of WGS-based MRD projects and foster the development of MRD-guided therapeutic strategies for a broad spectrum of cancers."</p>
<p>"We are thrilled to be collaborating with the esteemed NCCHE team on the SCRUM-MONSTAR-SCREEN-3 study. Investigators at NCCHE have been at the forefront of MRD research, leading some of the most groundbreaking and influential trials as part of SCRUM-MONSTAR-SCREEN, including CIRCULATE-Japan, which comprises GALAXY, VEGA, and ALTAIR in colorectal cancer patients," said Dale Muzzey, PhD, Chief Scientific Officer at Myriad Genetics. "We've designed Precise MRD to be highly sensitive for application across all cancer types and look forward to this study demonstrating its utility in cancer care."</p>


Global

Myriad Genetics And National Cancer Center Hospital East In Japan Collaborate On Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

ACAD

ACHC

AESI

AHCO

AIRS

ALEC

ALHC

AMBA

AMBC

APLS

ARKO

ARQT

ARRY

ATEC

AXON

BCSF

BECN

BGFV

BMBL

BWXT

BYND

CAVA

CBRL

CIVI

CLDT

CLNE

CLVT

CMLS

COMP

CPNG

CRDO

CYTK

EBAY

EHTH

ESPR

FARO

FLYW

FOUR

FSLR

FULC

GDOT

GLPI

GMRE

GSX Techedu Inc. American Depositary Shares

GOTU

GPOR

HRZN

HSIC

HURN

ICCC

ICFI

ICUI

IMAX

IMXI

INGN

IPAR

JAMF

KIND

KURA

KVYO

LGND

LGVN

Earnings Scheduled For February 27, 2024

<p><strong>Myriad Genetics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-02-27. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Myriad Genetics will report an <strong>earnings per share</strong> (EPS) of $0.01. </p>
<p>Myriad Genetics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Historical Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.05, which was followed by a 8.69% increase in the share price the next day.</p>
<p>Here's a look at Myriad Genetics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2023</strong></th>
<th><strong>Q2 2023</strong></th>
<th><strong>Q1 2023</strong></th>
<th><strong>Q4 2022</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.08</td>
<td>-0.08</td>
<td>-0.19</td>
<td>-0.16</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.03</td>
<td>-0.08</td>
<td>-0.21</td>
<td>-0.12</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>9.0%</td>
<td>-7.000000000000001%</td>
<td>-4.0%</td>
<td>13.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1708963300_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Myriad Genetics were trading at $22.72 as of February 23. Over the last 52-week period, shares are up 20.35%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/MYGN/earnings"><strong>To track all earnings releases for Myriad Genetics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Myriad Genetics Earnings Preview

<p>Goldman Sachs  analyst Matthew Sykes   maintains Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Buy and raises the price target from $28 to $31.</p>


Price Target

Goldman Sachs Maintains Buy on Myriad Genetics, Raises Price Target to $31

<p>Across the recent three months, 5 analysts have shared their insights on Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $22.2, along with a high estimate of $31.00 and a low estimate of $14.00. A decline of 1.33% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1706544069_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Myriad Genetics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$31.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>John Peterson</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Neutral</td>
<td>$23.00</td>
<td>-</td>
</tr>
<tr>
<td>Timothy Daley</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>-</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$23.00</td>
<td>-</td>
</tr>
<tr>
<td>Rachel Vatnsdal</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$14.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Myriad Genetics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Myriad Genetics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Myriad Genetics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Myriad Genetics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MYGN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Myriad Genetics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Get to Know Myriad Genetics Better</h2>
<p>Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.</p>
<h3>A Deep Dive into Myriad Genetics's Financials</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Myriad Genetics showcased positive performance, achieving a revenue growth rate of <strong>22.7%</strong> as of 30 September, 2023. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-31.94%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Myriad Genetics's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-8.64%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Myriad Genetics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-5.25%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Myriad Genetics's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.29</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Peeling Back The Layers: Exploring Myriad Genetics Through Analyst Insights

<p>&quot;With this acquisition, we&#39;re deepening our commitment to our oncology business while also generating a more effective way to scale and grow our tumor profiling and liquid biopsy tests, including operational efficiencies, reimbursement benefits and new clinical development opportunities,&quot; said Paul J. Diaz, president and CEO, Myriad Genetics. &quot;We&#39;d like to thank our longstanding partners at Intermountain Healthcare for the important progress they&#39;ve made in advancing precision oncology care. We look forward to continuing to build on this foundation to provide comprehensive genomic profiling options to the Intermountain Health System and its patients and providers that can help guide clinical care and improve patient outcomes.&quot;</p>


Myriad Genetics Acquires Precise Tumor, Precise Liquid And Laboratory From Intermountain Precision Genomics; Deal Terms Not Disclosed

<p><strong>Piper Sandler</strong>&nbsp;initiated coverage on<strong>&nbsp;Myriad Genetics Inc</strong>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mygn#NASDAQ">MYGN</a>), noting that many investors know the company as one of the earliest pioneers of genetic testing.</p>
<p>Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions. The company offers tests across multiple categories, including hereditary cancer, pharmacogenomics, and women&rsquo;s health.&nbsp;</p>
<p>It pioneered and was the market leader in BRCA testing for over ten years.</p>
<p>However, in the 2010s, Myriad faced challenges from ASP and market competition, struggling with effective execution.</p>
<p>The analysts David Westenberg and Jon Petersen write that CEO Paul Diaz has successfully addressed Myriad&rsquo;s operational and innovation challenges.&nbsp;</p>
<p>The analysts initiate with a Neutral rating and a&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/quote/MYGN/analyst-ratings" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">price target of $23</a>.</p>
<p>They observe a significant improvement in the core business, which has largely resumed growth, positioning the company to regain its leadership role in laboratory genetics.</p>
<p>In contrast to other public esoteric labs, Myriad boasts a favorable balance sheet and robust operating infrastructure. Piper analysts anticipate competitive advancements in BRCA, oncology, and reproductive health testing within the coming year that could significantly drive further growth for the company.</p>
<p>Piper anticipates encountering minor challenges due to pricing pressures affecting various product lines, notably within the hereditary cancer&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/money/best-sectors-to-invest-in-right-now/" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">sector</a>.&nbsp;</p>
<p>This area faces continual reimbursement reductions and heightened competition, contributing to these headwinds.</p>
<p><strong>Price Action:&nbsp;</strong>MYGN shares are down 0.25% at $20.27 on the last check Thursday.</p>
<p><em>Photo via Wikimedia Commons</em></p>


Genetic Testing Pioneer Myriad Genetics' Evolution Draws Analyst Attention Amid New Product(s) Anticipation

Management

Myriad Genetics Appoints Of Scott Leffler As CFO Effective Jan. 29, 2024; Succeeds Bryan Riggsbee; Riggsbee Will Continue As Strategic Advisor Through March 31, 2024, To Ensure A Smooth Transition

<p>During the last three months, 4 analysts shared their evaluations of Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $20.0, a high estimate of $23.00, and a low estimate of $14.00. Witnessing a positive shift, the current average has risen by 17.65% from the previous average price target of $17.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2023/1703160011_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The perception of Myriad Genetics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Peterson</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Neutral</td>
<td>$23.00</td>
<td>-</td>
</tr>
<tr>
<td>Timothy Daley</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>-</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$23.00</td>
<td>-</td>
</tr>
<tr>
<td>Rachel Vatnsdal</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$14.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Myriad Genetics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Myriad Genetics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Myriad Genetics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Myriad Genetics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MYGN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Myriad Genetics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Myriad Genetics</h2>
<p>Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.</p>
<h3>Unraveling the Financial Story of Myriad Genetics</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Myriad Genetics displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately <strong>22.7%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Myriad Genetics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-31.94%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Myriad Genetics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-8.64%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Myriad Genetics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-5.25%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>0.29</strong>, Myriad Genetics faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Evaluating Myriad Genetics: Insights From 4 Financial Analysts

<p>Piper Sandler  analyst John Peterson   initiates coverage on Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Neutral rating and announces Price Target of $23.</p>


Piper Sandler Initiates Coverage On Myriad Genetics with Neutral Rating, Announces Price Target of $23

<p><a href="https://www.globenewswire.com/Tracker?data=8TwH4PAnEbzfXIdZb-A5cjS_6_cFXGdrL5wli5pGNglfndkoXD1ZBUqn6Yn4EmygS2C7zkk3S-tfmr6juSrvDE-CZc247dVuEp8LIPTIEKVfDif8EqiILQoNOWZsMGnh_JfpxFSrp3-PHhZIY00AIqwr9wfiKwJzinTnsnUseNA=" target="_blank">Myriad Genetics, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), a leader in genetic testing and precision medicine, today announced the launch of the&nbsp;<a href="https://www.globenewswire.com/Tracker?data=8TwH4PAnEbzfXIdZb-A5cp36Yx1CdjlLXSDe-U2dPq_4uyt-99g3n4hZkfj9GNW5Y9nuAS8qXfFlHUbFCr-m5BgNk_pypUSWFH_uWSWkZVV9Iblex8CrxnyWPPEi9NZ9" target="_blank">Myriad Collaborative Research Registry</a>&trade; (MCRR). Formerly known as the Precise Treatment Registry, the MCRR includes new data across germline and tumor testing results from Myriad&#39;s cancer products on more than one million patients. The latest enhancements make the MCRR one of the largest pan-cancer registries freely available for research use and supports transparent clinical data sharing to advance the field.</p>


Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care

<p>Wells Fargo  analyst Timothy Daley   initiates coverage on Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Equal-Weight rating and announces Price Target of $20.</p>


Wells Fargo Initiates Coverage On Myriad Genetics with Equal-Weight Rating, Announces Price Target of $20

Notable earnings after Tuesday's close

Myriad Genetics Non-GAAP EPS of $0.04 beats by $0.03, revenue of $196.6M beats by $1.97M

Myriad Genetics, Inc. 2023 Q4 - Results - Earnings Call Presentation

In a report released yesterday, Daniel Brennan from TD Cowen maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a price tar...

Myriad Genetics: Hold Rating Maintained Amid Balanced Performance and Cautious Outlook

Myriad Genetics, Inc. (MYGN) Q4 2023 Earnings Call Transcript

In a report released today, Rachel Vatnsdal from J.P. Morgan maintained a Sell rating on Myriad Genetics (MYGN – Research Report), with a price tar...

Myriad Genetics: A Sell Rating Amidst Profitability and Growth Concerns

Piper Sandler analyst David Westenberg reiterated a Hold rating on Myriad Genetics (MYGN – Research Report) today and set a price target of $23.00....

Piper Sandler Reaffirms Their Hold Rating on Myriad Genetics (MYGN)

Myriad Genetics (MYGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on February 27. Analyst Puneet Soud...

Myriad Genetics: Hold Rating Amidst Growth and Market Uncertainty

In a report released today, David Westenberg from Piper Sandler maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a price ...

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Myriad Genetics Stock (NASDAQ:MYGN), Short Interest Report

People Also Watch